Lv43
523 积分 2021-03-23 加入
PCSK9 inhibitors: an updated patent review 2024–2025
1小时前
已完结
The evolving landscape of obesity pharmacotherapy
1天前
已完结
Tafolecimab: First Approval
4天前
已完结
Navigating First‐in‐Human and Early‐Phase Patient Studies: Study Designs, Risk Mitigation, and Population Selection Challenges
12天前
已完结
Physiological and pathological roles of lipogenesis
14天前
已完结
Dyslipidemia Evaluation and Management
29天前
已完结
Cardiovascular Risk Reclassification With the 2026 Dyslipidemia Guideline
29天前
已完结
Cardiovascular Outcomes Research A Clinician’s Guide to Cardiovascular Epidemiology and Clinical Outcomes Trials
1个月前
已完结
The story of amylin: from physiology to therapy
1个月前
已完结
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
1个月前
已完结
皖公网安备34019202002308
